Astellas Pharma Inc
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to m… Read more
Astellas Pharma Inc (ALPMF) - Total Liabilities
Latest total liabilities as of December 2025: $1.84 Trillion USD
Based on the latest financial reports, Astellas Pharma Inc (ALPMF) has total liabilities worth $1.84 Trillion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Astellas Pharma Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how Astellas Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Astellas Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Astellas Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yum China Holdings Inc
NYSE:YUMC
|
USA | $4.65 Billion |
|
Global Payments Inc
NYSE:GPN
|
USA | $24.46 Billion |
|
Tbea Co Ltd
SHG:600089
|
China | CN¥131.46 Billion |
|
B3 S.A. - Brasil Bolsa Balcão
PINK:BOLSY
|
USA | $27.54 Billion |
|
PTT Exploration & Production
PINK:PEXNY
|
USA | $414.37 Billion |
|
Fresenius SE & Co. KGaA
PINK:FSNUF
|
USA | $23.23 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Astellas Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Astellas Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Astellas Pharma Inc (2004–2025)
The table below shows the annual total liabilities of Astellas Pharma Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $1.83 Trillion | -7.46% |
| 2024-03-31 | $1.97 Trillion | +108.06% |
| 2023-03-31 | $948.56 Billion | +8.77% |
| 2022-03-31 | $872.09 Billion | -1.74% |
| 2021-03-31 | $887.51 Billion | -13.75% |
| 2020-03-31 | $1.03 Trillion | +60.97% |
| 2019-03-31 | $639.25 Billion | +8.36% |
| 2018-03-31 | $589.92 Billion | +7.44% |
| 2017-03-31 | $549.09 Billion | +1.66% |
| 2016-03-31 | $540.13 Billion | +13.55% |
| 2015-03-31 | $475.66 Billion | +23.67% |
| 2014-03-31 | $384.63 Billion | +0.29% |
| 2013-03-31 | $383.54 Billion | +0.27% |
| 2012-03-31 | $382.51 Billion | +21.82% |
| 2011-03-31 | $314.00 Billion | +1.21% |
| 2010-03-31 | $310.24 Billion | -2.51% |
| 2009-03-31 | $318.23 Billion | -3.07% |
| 2008-03-31 | $328.29 Billion | -11.68% |
| 2007-03-31 | $371.71 Billion | +1.23% |
| 2006-03-31 | $367.18 Billion | +115.88% |
| 2005-03-31 | $170.09 Billion | -2.72% |
| 2004-03-31 | $174.84 Billion | -- |